Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen

Bibliographic Details
Main Author: Marchiori M.S.*
Publication Date: 2022
Other Authors: Glombowsky P.*, Fracasso M., Silva A.D., Schetinger M.R.C., da Silva I.G., Sareta L., Mendes R.E., da Silva A.S.*
Format: Article
Language: eng
Source: Repositório Institucional da Udesc
dARK ID: ark:/33523/001300000dkst
Download full: https://repositorio.udesc.br/handle/UDESC/2808
Summary: © 2022, The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.This study aims to evaluate whether the consumption of homeopathic products (Orgafig®) in Wistar rats (Rattus norvegicus) can protect the liver against two challenges (a) antipyretic/analgesic (acetaminophen), and (b) feed contaminated with aflatoxin B1. We used 60 animals divided into six groups of ten animals each (a) negative control (NC) that did not receive the drugs and was not challenged with aflatoxin B1; (b) negative control + Orgafig® (NC -H) receiving only homeopathy; (c) positive control for aflatoxin B1 (CP-A) receiving a mycotoxin-contaminated diet; (d) positive control for acetaminophen (CP-P) receiving daily doses of the drug orally; (e) Orgafig® + aflatoxin (HA) receiving homeopathic and challenged with diet contaminated with aflatoxin B1; and (f) Orgafig® + acetaminophen (HP) receiving homeopathic and were challenged with doses of acetaminophen. The Orgafig® was added to the diet for 32 days before the challenge with preventive intent. Then, a challenge was conducted over 10 days using aflatoxin B1 via diet and oral acetaminophen doses. Rats that consumed aflatoxin grew more slowly than the other groups. There were increases in serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), indicating liver damage in animals from the positive control groups (CP-A and CP-P); this did not occur in animals with preventive use of Orgafig® (HA and HP). Likewise, in the liver, there was an increase in cell injury and oxidative stress biomarkers (reactive oxygen species, thiobarbituric acid reactive substances, and glutathione S-transferase) that also signal liver damage in the positive control rats (CP-A and CP-P); this did not occur in animals with preventive or Orgafig® use (HA and HP). These results suggest that the prophylactic use of the Orgafig® minimizes the adverse effects caused by the daily consumption of aflatoxin B1 and acetaminophen, which are known for hepatotoxic action when used in high doses or for prolonged periods.
id UDESC-2_71164ce279de7cbf1b4c5c2e37dfdc76
oai_identifier_str oai:repositorio.udesc.br:UDESC/2808
network_acronym_str UDESC-2
network_name_str Repositório Institucional da Udesc
repository_id_str 6391
spelling Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen© 2022, The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.This study aims to evaluate whether the consumption of homeopathic products (Orgafig®) in Wistar rats (Rattus norvegicus) can protect the liver against two challenges (a) antipyretic/analgesic (acetaminophen), and (b) feed contaminated with aflatoxin B1. We used 60 animals divided into six groups of ten animals each (a) negative control (NC) that did not receive the drugs and was not challenged with aflatoxin B1; (b) negative control + Orgafig® (NC -H) receiving only homeopathy; (c) positive control for aflatoxin B1 (CP-A) receiving a mycotoxin-contaminated diet; (d) positive control for acetaminophen (CP-P) receiving daily doses of the drug orally; (e) Orgafig® + aflatoxin (HA) receiving homeopathic and challenged with diet contaminated with aflatoxin B1; and (f) Orgafig® + acetaminophen (HP) receiving homeopathic and were challenged with doses of acetaminophen. The Orgafig® was added to the diet for 32 days before the challenge with preventive intent. Then, a challenge was conducted over 10 days using aflatoxin B1 via diet and oral acetaminophen doses. Rats that consumed aflatoxin grew more slowly than the other groups. There were increases in serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), indicating liver damage in animals from the positive control groups (CP-A and CP-P); this did not occur in animals with preventive use of Orgafig® (HA and HP). Likewise, in the liver, there was an increase in cell injury and oxidative stress biomarkers (reactive oxygen species, thiobarbituric acid reactive substances, and glutathione S-transferase) that also signal liver damage in the positive control rats (CP-A and CP-P); this did not occur in animals with preventive or Orgafig® use (HA and HP). These results suggest that the prophylactic use of the Orgafig® minimizes the adverse effects caused by the daily consumption of aflatoxin B1 and acetaminophen, which are known for hepatotoxic action when used in high doses or for prolonged periods.2024-12-05T20:16:43Z2022info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlep. 979 - 9851618-565X10.1007/s00580-022-03398-2https://repositorio.udesc.br/handle/UDESC/2808ark:/33523/001300000dkstComparative Clinical Pathology316Marchiori M.S.*Glombowsky P.*Fracasso M.Silva A.D.Schetinger M.R.C.da Silva I.G.Sareta L.Mendes R.E.da Silva A.S.*engreponame:Repositório Institucional da Udescinstname:Universidade do Estado de Santa Catarina (UDESC)instacron:UDESCinfo:eu-repo/semantics/openAccess2024-12-07T20:39:50Zoai:repositorio.udesc.br:UDESC/2808Biblioteca Digital de Teses e Dissertaçõeshttps://pergamumweb.udesc.br/biblioteca/index.phpPRIhttps://repositorio-api.udesc.br/server/oai/requestri@udesc.bropendoar:63912024-12-07T20:39:50Repositório Institucional da Udesc - Universidade do Estado de Santa Catarina (UDESC)false
dc.title.none.fl_str_mv Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
title Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
spellingShingle Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
Marchiori M.S.*
title_short Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
title_full Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
title_fullStr Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
title_full_unstemmed Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
title_sort Orgafig® daily intake minimizes oxidative stress and tissue damage in the liver in the face of challenges with aflatoxin in the diet and consecutive doses of acetaminophen
author Marchiori M.S.*
author_facet Marchiori M.S.*
Glombowsky P.*
Fracasso M.
Silva A.D.
Schetinger M.R.C.
da Silva I.G.
Sareta L.
Mendes R.E.
da Silva A.S.*
author_role author
author2 Glombowsky P.*
Fracasso M.
Silva A.D.
Schetinger M.R.C.
da Silva I.G.
Sareta L.
Mendes R.E.
da Silva A.S.*
author2_role author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Marchiori M.S.*
Glombowsky P.*
Fracasso M.
Silva A.D.
Schetinger M.R.C.
da Silva I.G.
Sareta L.
Mendes R.E.
da Silva A.S.*
description © 2022, The Author(s), under exclusive licence to Springer-Verlag London Ltd., part of Springer Nature.This study aims to evaluate whether the consumption of homeopathic products (Orgafig®) in Wistar rats (Rattus norvegicus) can protect the liver against two challenges (a) antipyretic/analgesic (acetaminophen), and (b) feed contaminated with aflatoxin B1. We used 60 animals divided into six groups of ten animals each (a) negative control (NC) that did not receive the drugs and was not challenged with aflatoxin B1; (b) negative control + Orgafig® (NC -H) receiving only homeopathy; (c) positive control for aflatoxin B1 (CP-A) receiving a mycotoxin-contaminated diet; (d) positive control for acetaminophen (CP-P) receiving daily doses of the drug orally; (e) Orgafig® + aflatoxin (HA) receiving homeopathic and challenged with diet contaminated with aflatoxin B1; and (f) Orgafig® + acetaminophen (HP) receiving homeopathic and were challenged with doses of acetaminophen. The Orgafig® was added to the diet for 32 days before the challenge with preventive intent. Then, a challenge was conducted over 10 days using aflatoxin B1 via diet and oral acetaminophen doses. Rats that consumed aflatoxin grew more slowly than the other groups. There were increases in serum activities of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (AP), indicating liver damage in animals from the positive control groups (CP-A and CP-P); this did not occur in animals with preventive use of Orgafig® (HA and HP). Likewise, in the liver, there was an increase in cell injury and oxidative stress biomarkers (reactive oxygen species, thiobarbituric acid reactive substances, and glutathione S-transferase) that also signal liver damage in the positive control rats (CP-A and CP-P); this did not occur in animals with preventive or Orgafig® use (HA and HP). These results suggest that the prophylactic use of the Orgafig® minimizes the adverse effects caused by the daily consumption of aflatoxin B1 and acetaminophen, which are known for hepatotoxic action when used in high doses or for prolonged periods.
publishDate 2022
dc.date.none.fl_str_mv 2022
2024-12-05T20:16:43Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv 1618-565X
10.1007/s00580-022-03398-2
https://repositorio.udesc.br/handle/UDESC/2808
dc.identifier.dark.fl_str_mv ark:/33523/001300000dkst
identifier_str_mv 1618-565X
10.1007/s00580-022-03398-2
ark:/33523/001300000dkst
url https://repositorio.udesc.br/handle/UDESC/2808
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Comparative Clinical Pathology
31
6
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv p. 979 - 985
dc.source.none.fl_str_mv reponame:Repositório Institucional da Udesc
instname:Universidade do Estado de Santa Catarina (UDESC)
instacron:UDESC
instname_str Universidade do Estado de Santa Catarina (UDESC)
instacron_str UDESC
institution UDESC
reponame_str Repositório Institucional da Udesc
collection Repositório Institucional da Udesc
repository.name.fl_str_mv Repositório Institucional da Udesc - Universidade do Estado de Santa Catarina (UDESC)
repository.mail.fl_str_mv ri@udesc.br
_version_ 1842258120616706048